Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
about
Translational biomarkers of neurotoxicity: a Health and Environmental Sciences Institute perspective on the way forwardUnlocking proteomic heterogeneity in complex diseases through visual analyticsHow drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionWhen Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility CrisisManaging risks in drug discovery: reproducibility of published findingsChanging R&D; models in research-based pharmaceutical companiesBridging academic science and clinical research in the search for novel targeted anti-cancer agentsProgress and promise in understanding the genetic basis of common diseasesTranslating extracellular microRNA into clinical biomarkers for drug-induced toxicity: from high-throughput profiling to validationOn the predictive utility of animal models of osteoarthritisGenetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plansImproving and accelerating drug development for nervous system disordersCellular Biomechanics in Drug Screening and Evaluation: MechanopharmacologyCETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil.Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through public-private partnershipsOpportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big DataThe promises of quantitative systems pharmacology modelling for drugĀ developmentThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityIn Vitro Testing of Biomaterials for Neural Repair: Focus on Cellular Systems and High-Content AnalysisImmune cell screening of a nanoparticle library improves atherosclerosis therapyTYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traitsInvestigating Apoptozole as a Chemical Probe for HSP70 InhibitionThe ChEMBL database in 2017Human-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop.Human genetics as a model for target validation: finding new therapies for diabetes.Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testingHow many molecules does it take to tell a story? Case studies, language, and an epistemic view of medicinal chemistry.The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.Toxicologic Pathology Analysis for Translational Neuroscience: Improving Human Risk Assessment Using Optimized Animal Data.ZeGlobalTox: An Innovative Approach to Address Organ Drug Toxicity Using Zebrafish.Importance of Drug Pharmacokinetics at the Site of ActionTimelines of translational science: From technology initiation to FDA approvalThe Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D.When Science is Not Enough: A Framework Towards More Customer-Focused Drug Development.Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?The support of human genetic evidence for approved drug indications.Novel insights in drug metabolism by MS imaging.Translating slow-binding inhibition kinetics into cellular and in vivo effectsTaking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and SchizophreniaMesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We With Cardiac Cell-Based Therapy?
P2860
Q23920632-C8D8A196-E627-41AE-9512-B0CB8864F98BQ23921986-64601CB3-E2E9-4C93-8828-F0A2212B9956Q24273350-FAD6BFE7-C354-429E-99D0-C9A9CBD027C3Q24288687-CA76DCA9-9B6A-4CC9-884D-5F2F3D13900FQ24289508-D80472B6-7F71-4E61-9C69-BDEDD5CD18FCQ26749511-979E6E34-7C11-4784-A737-4448B9F97381Q26771396-7049404C-54EB-445B-B85F-A91606AA172EQ26772104-C93A4E44-5E70-45E6-8599-2CD10AD02C31Q26778915-AD713796-CC37-4D22-A2EF-83737BFE3E4AQ26781301-5C080144-3219-40F1-9B7E-9212A1900E4EQ26801647-B5254BEE-2639-44E9-B0F5-ABA9647A29E3Q27008349-F43F1683-C151-4016-BED8-ED79E1BEA3DFQ27021118-FBB8A288-2936-47B0-9A69-DEC5DA678721Q27323225-D5E32FD5-39C3-4BF0-95DF-ED42430B9DE0Q28069462-5A0C109B-DC25-4C5F-8E40-0A9224D1946BQ28076506-A570E675-E9CB-4F58-9A06-93CDC32A4AAFQ28077650-98EB2F8F-9772-41F8-9A2F-D167CD4A81A1Q28080256-34F17341-3CD1-445A-92CC-22015A3866BDQ28387048-2D258CE8-5473-450B-877E-731699029BFDQ28393434-F5F6253F-2511-4328-AC77-54ED8EFAD698Q28545832-BCAAD512-3926-4F5C-97F8-ABD2A0CC60ACQ28550180-0D694E0B-E6CD-4C9F-BAD1-96870D85E8D4Q28584450-D17811DC-10DC-4550-8A89-0DD31165CEF3Q28596483-8A8D7633-45A5-4219-9B3A-028255967A59Q30234640-3B41C441-F5FC-4C51-9FDB-C5D511DBA15EQ30358385-0C7CA7C8-A277-4981-BF82-5351EDB65C8DQ30373202-9EEAC67F-7AFE-437D-A8E5-AE9C9C194162Q30854543-38467705-F005-4A13-9574-00DC90AE61AEQ31063026-2E64855F-7C8A-46DA-8712-7DD2DEA4A6F4Q33624909-C82C86E8-986E-4350-8741-907A3AAC9076Q33648045-DF6093EB-3816-4011-9035-F8B65ABBA121Q33648237-B5086A5D-F100-41D8-B958-8155FCD3BBC2Q33845748-9074FE30-40BA-45C8-A229-7C8C5C2ED4AEQ33890787-681EDE2E-BBB8-4245-AC9A-F5967C6558B1Q34458090-A036F8DC-0B2E-4FD8-B1C2-D4BC492FF3E2Q35677036-DC5EC271-E41A-466B-AE87-97796D134ED9Q35936145-88E334FD-30FE-482C-8A1A-14D4C5B50533Q35954896-1624A176-1932-4D8E-AECE-B60F7EC09D34Q36063627-EA223495-5957-4F8A-A6C5-BB2F7D9EAEF7Q36064005-1F621A60-5BC6-42C0-AF1C-FFDFCB28DDB7
P2860
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.
description
article cientĆfic
@ca
article scientifique
@fr
articol ČtiinČific
@ro
articolo scientifico
@it
artigo cientĆfico
@gl
artigo cientĆfico
@pt
artigo cientĆfico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artĆculo cientĆfico
@es
name
Lessons learned from the fate ...... a five-dimensional framework.
@en
type
label
Lessons learned from the fate ...... a five-dimensional framework.
@en
prefLabel
Lessons learned from the fate ...... a five-dimensional framework.
@en
P2093
P356
P1476
Lessons learned from the fate ...... a five-dimensional framework.
@en
P2093
David Cook
Dearg Brown
Gemma Satterthwaite
Menelas N Pangalos
Paul Morgan
Robert Alexander
Ruth March
P2888
P304
P356
10.1038/NRD4309
P577
2014-05-16T00:00:00Z